These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29712560)

  • 1. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study.
    Bhanpuri NH; Hallberg SJ; Williams PT; McKenzie AL; Ballard KD; Campbell WW; McCarter JP; Phinney SD; Volek JS
    Cardiovasc Diabetol; 2018 May; 17(1):56. PubMed ID: 29712560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes.
    Athinarayanan SJ; Hallberg SJ; McKenzie AL; Lechner K; King S; McCarter JP; Volek JS; Phinney SD; Krauss RM
    Cardiovasc Diabetol; 2020 Dec; 19(1):208. PubMed ID: 33292205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study.
    Hallberg SJ; McKenzie AL; Williams PT; Bhanpuri NH; Peters AL; Campbell WW; Hazbun TL; Volk BM; McCarter JP; Phinney SD; Volek JS
    Diabetes Ther; 2018 Apr; 9(2):583-612. PubMed ID: 29417495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial.
    Athinarayanan SJ; Adams RN; Hallberg SJ; McKenzie AL; Bhanpuri NH; Campbell WW; Volek JS; Phinney SD; McCarter JP
    Front Endocrinol (Lausanne); 2019; 10():348. PubMed ID: 31231311
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement in patient-reported sleep in type 2 diabetes and prediabetes participants receiving a continuous care intervention with nutritional ketosis.
    Siegmann MJ; Athinarayanan SJ; Hallberg SJ; McKenzie AL; Bhanpuri NH; Campbell WW; McCarter JP; Phinney SD; Volek JS; Van Dort CJ
    Sleep Med; 2019 Mar; 55():92-99. PubMed ID: 30772699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of a Nutritional Intervention on Glycemic Control and Cardiovascular Risk Markers in Type 2 Diabetes.
    Minari TP; Manzano CF; Tácito LHB; Yugar LBT; Sedenho-Prado LG; Rubio TA; Pires AC; Vilela-Martin JF; Cosenso-Martin LN; Moreno H; Yugar-Toledo JC
    Nutrients; 2024 May; 16(9):. PubMed ID: 38732624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial.
    Tay J; Luscombe-Marsh ND; Thompson CH; Noakes M; Buckley JD; Wittert GA; Yancy WS; Brinkworth GD
    Diabetes Care; 2014 Nov; 37(11):2909-18. PubMed ID: 25071075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study.
    Vilar-Gomez E; Athinarayanan SJ; Adams RN; Hallberg SJ; Bhanpuri NH; McKenzie AL; Campbell WW; McCarter JP; Phinney SD; Volek JS; Chalasani N
    BMJ Open; 2019 Feb; 9(2):e023597. PubMed ID: 30803948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial.
    Tay J; Thompson CH; Luscombe-Marsh ND; Wycherley TP; Noakes M; Buckley JD; Wittert GA; Yancy WS; Brinkworth GD
    Diabetes Obes Metab; 2018 Apr; 20(4):858-871. PubMed ID: 29178536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial.
    Tay J; Luscombe-Marsh ND; Thompson CH; Noakes M; Buckley JD; Wittert GA; Yancy WS; Brinkworth GD
    Am J Clin Nutr; 2015 Oct; 102(4):780-90. PubMed ID: 26224300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K; Koshizaka M; Tokuyama H; Tokuyama T; Ishikawa T; Maezawa Y; Takemoto M; Yokote K
    Lipids Health Dis; 2018 Mar; 17(1):51. PubMed ID: 29544483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous care intervention with carbohydrate restriction improves physical function of the knees among patients with type 2 diabetes: a non-randomized study.
    Lyman KS; Athinarayanan SJ; McKenzie AL; Pearson CL; Adams RN; Hallberg SJ; McCarter JP; Volek JS; Phinney SD; Andrawis JP
    BMC Musculoskelet Disord; 2022 Mar; 23(1):297. PubMed ID: 35351093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in glucose metabolism and insulin sensitivity with a low-carbohydrate diet in obese patients with type 2 diabetes.
    Krebs JD; Bell D; Hall R; Parry-Strong A; Docherty PD; Clarke K; Chase JG
    J Am Coll Nutr; 2013; 32(1):11-7. PubMed ID: 24015695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial.
    Jia W; Zhang P; Zhu D; Duolikun N; Li H; Bao Y; Li X;
    PLoS Med; 2021 Sep; 18(9):e1003754. PubMed ID: 34547030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.